GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the development of highly diverse, functional antibodies for infectious disease utilizing Surge technology at the 10th Annual Protein & Antibody Engineering Summit (PEGS) in Europe. Dr. Johnson’s invited podium presentation is titled […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-11-12 14:36:122018-11-12 14:37:53GigaGen CEO David Johnson to Present on Development of Recombinant Polyclonal Therapies for Infectious Disease at 10th Annual PEGS Summit Europe
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Adam Adler, Ph.D., Vice President of Research and Development, will present on the antibody drug candidates discovered by the company’s industry-leading Surge technology against 17 unique immuno-oncology targets. […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-11-09 09:17:002018-11-09 09:19:44GigaGen to Present Data on Immuno-Oncology Pipeline at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
“Scrappy.” That’s a one-word summation of GigaGen’s approach to both the business and science of biotech. “When you’re a new company, you have to be scrappy and clever. When I founded GigaGen in 2011, I didn’t have a big war chest of money, so I had to find a way to be competitive. That’s central […]
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 18th Biennial Meeting of the European Society for Immunodeficiencies (ESID). Rena Mizrahi, Ph.D., director of protein engineering, will present on the company’s proprietary recombinant hyperimmune gammaglobulin program. The conference takes place October 24-27, 2018, at the Centro de Congressos […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-10-26 07:10:412018-10-26 07:11:16GigaGen to Present Data on Recombinant Hyperimmune Gammaglobulin at the 18th Biennial Meeting of the European Society for Immunodeficiencies
The National Institutes of Health (NIH) is a household name in the drug discovery and development industry. Among the NIH’s many recipients is South San Francisco, Calif.-based GigaGen, a biotherapeutics company. GigaGen’s CEO, Dr. Dave Johnson, took some time to talk with us about how NIH funding and participation in the I-Corps commercialization program helped […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-08-14 11:06:482018-08-20 11:13:36Drug Discovery News: GigaGen CEO Dave Johnson, PhD, discusses I/O product development and impact of NIH grant support on company growth
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-08-03 11:30:022018-08-03 11:31:13GigaGen CEO Dave Johnson interviewed by Moira Gunn on Biotech Nation Radio
Antibodies have been used since the late 1980s as therapies to treat serious diseases, and demand is soaring to new heights today. However, conventional antibody drug discovery technologies are labor-intensive and slow. Pharmaceutical companies select drug candidates from just a small fraction of the antibodies that exist in a natural immune repertoire and have limited […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-06-06 11:10:312018-06-06 11:10:31Drug Development and Delivery: GigaGen CEO Dave Johnson discusses Why Understanding Immune Dysregulation is the Key to Drug Development
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Sheila M. Keating, Ph.D., has joined the company as Director, Immunology. Dr. Keating will lead clinical development of GigaGen’s recombinant hyperimmune gammaglobulin product in collaboration with pharmaceutical partner Grifols. Read the full press release.
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-05-03 08:14:352018-05-03 08:14:35GigaGen Announces Appointment of Sheila M. Keating, Ph.D., as Director, Immunology
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the discovery of unique and functional antibodies utilizing Surge technology at the 14th Annual PEGS Summit. Dr. Johnson’s invited podium presentation is titled “Discovery of High-Affinity Human PD-1 and LAG-3 Antibodies Using […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-04-30 06:02:292018-04-30 06:03:59GigaGen CEO David Johnson to Present on the Power of Surge Technology to Discover Unique Immuno-oncology Antibodies at 14th Annual PEGS Summit
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present data from the company’s proprietary Surge platform at the American Association for Cancer Research (AACR) Annual Meeting 2018. The conference will take place April 14-18, 2018, at the McCormick Place in Chicago. Read the full […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-04-09 09:01:312018-04-09 09:01:31GigaGen CEO David Johnson to Present Data from Surge Platform at American Association for Cancer Research Annual Meeting 2018
Our annual survey highlights how immune-oncology and screens based on the application of cutting-edge omics technologies are providing a launchpad for a succession of startups interrogating biology across biomedicine. Read the full story.
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-04-06 07:39:462018-04-06 07:40:42Nature Biotechnology: GigaGen Recognized as One of the Top Biotech Startups Funded in 2017
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, presented preclinical research on its industry-leading Surge™ technology at the 2018 Keystone Symposia on Antibodies as Drugs: Translating Molecules into Treatments. In its research, GigaGen used Surge, a high-throughput single cell droplet microfluidic technology, to rapidly discover high-affinity, fully human antibody drug candidates against 17 immuno-oncology […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-02-27 08:03:122018-02-27 08:03:12GigaGen Presents Methods for Rapid Immuno-Oncology Antibody Discovery at 2018 Keystone Symposia on Antibodies as Drugs
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Jan Fredrik Simons, Ph.D., has joined the company as Senior Director, Technology. Read the full press release.
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-02-26 06:40:092018-02-26 10:49:41GigaGen Announces Appointment of Jan Fredrik Simons, Ph.D., as Senior Director, Technology
David S. Johnson, PhD, MBA, Chief Executive Officer and Co-Founder, GigaGen, speaks to SCRIP about the company’s pipeline and business strategy. Watch the video.
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, will be presenting the findings of its research on novel approaches to antibody development and T cell discovery for diseases of immune dysregulation at two upcoming Keystone Symposia conferences. The first conference, “Emerging Cellular Therapies: T Cells and Beyond,” will take place Feb. 11-15 in Keystone, […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-02-12 05:40:552018-02-12 05:40:55GigaGen to Present Novel Antibody Development and T Cell Discovery Methods at 2018 Keystone Symposia Conferences
I think Silicon Valley’s most valuable asset is a ruthless focus on experimenting with product- market fit. Silicon Valley software companies have the mentality of pushing out products, getting market feedback, and then going back to the drawing board if the market responds poorly. Imperfect products are a learning experience — an experiment — rather […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-02-08 06:10:402018-02-21 08:29:27Life Science Leader: GigaGen CEO Dave Johnson discusses what Drug Developers can learn from Silicon Valley
GigaGen Inc., a biopharmaceutical company developing a pipeline of novel antibody therapies, has published a study in collaboration with authors from a leading antibody drug developer that sheds new light on methods for increasing the success of antibody discovery in mice. The study, “A natively paired antibody library yields drug leads with higher sensitivity and […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-02-05 08:30:352018-02-05 08:31:08Natively Paired Antibodies Are Better: Study by GigaGen in Collaboration with Global Biopharmaceutical Company Describes Novel Approach to Identifying Antibodies with High Therapeutic Potential
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that in order to expand operations it has moved to larger office facilities located at One Tower Place, Suite 750, in South San Francisco, CA. GigaGen now occupies the 7th floor of the building, with the roughly 15,000 square foot area affording ample state-of-the-art […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-01-23 08:00:042018-01-24 06:05:57GigaGen Announces New Office Space in South San Francisco
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, has been awarded a $3 million grant from the National Institutes of Health (NIH) to advance its next-generation plasma therapy for patients with immune deficiencies. GigaGen will use the funds to develop a natural repertoire antibody protein expression system, laying the foundation for a recombinant immunoglobulin […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-01-16 08:00:042018-01-24 06:04:51GigaGen Receives NIH Grant to Develop Production Technology for Recombinant Intravenous Immunoglobulin
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the disclosure of 17 immuno-oncology targets the company is pursuing within their robust internal pipeline. GigaGen has completed a large discovery and development effort of fully human antibody drug candidates against the following cancer targets: PD-1, LAG-3, OX40, CSF1R, ICOS, VISTA, CD47, B7-H4, CD27, […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00David Johnsonhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngDavid Johnson2017-12-19 17:09:462017-12-19 13:02:45GigaGen to Develop Human Antibodies Against 17 Immuno-oncology Targets
GigaGen CEO David Johnson to Present on Development of Recombinant Polyclonal Therapies for Infectious Disease at 10th Annual PEGS Summit Europe
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the development of highly diverse, functional antibodies for infectious disease utilizing Surge technology at the 10th Annual Protein & Antibody Engineering Summit (PEGS) in Europe. Dr. Johnson’s invited podium presentation is titled […]
GigaGen to Present Data on Immuno-Oncology Pipeline at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Adam Adler, Ph.D., Vice President of Research and Development, will present on the antibody drug candidates discovered by the company’s industry-leading Surge technology against 17 unique immuno-oncology targets. […]
Genetic Engineering & Biotechnology News: Microfluidic dragnet catches most-wanted antibodies – GigaGen exhaustively interrogates antibodies to find drug candidates
News, Uncategorized“Scrappy.” That’s a one-word summation of GigaGen’s approach to both the business and science of biotech. “When you’re a new company, you have to be scrappy and clever. When I founded GigaGen in 2011, I didn’t have a big war chest of money, so I had to find a way to be competitive. That’s central […]
GigaGen to Present Data on Recombinant Hyperimmune Gammaglobulin at the 18th Biennial Meeting of the European Society for Immunodeficiencies
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 18th Biennial Meeting of the European Society for Immunodeficiencies (ESID). Rena Mizrahi, Ph.D., director of protein engineering, will present on the company’s proprietary recombinant hyperimmune gammaglobulin program. The conference takes place October 24-27, 2018, at the Centro de Congressos […]
Drug Discovery News: GigaGen CEO Dave Johnson, PhD, discusses I/O product development and impact of NIH grant support on company growth
News, UncategorizedThe National Institutes of Health (NIH) is a household name in the drug discovery and development industry. Among the NIH’s many recipients is South San Francisco, Calif.-based GigaGen, a biotherapeutics company. GigaGen’s CEO, Dr. Dave Johnson, took some time to talk with us about how NIH funding and participation in the I-Corps commercialization program helped […]
GigaGen CEO Dave Johnson interviewed by Moira Gunn on Biotech Nation Radio
News, UncategorizedListen to Moira Gunn’s interview with GigaGen CEO Dave Johnson, PhD, on developing next generation I/O drugs to fight cancer on Biotech Nation Radio
Drug Development and Delivery: GigaGen CEO Dave Johnson discusses Why Understanding Immune Dysregulation is the Key to Drug Development
News, UncategorizedAntibodies have been used since the late 1980s as therapies to treat serious diseases, and demand is soaring to new heights today. However, conventional antibody drug discovery technologies are labor-intensive and slow. Pharmaceutical companies select drug candidates from just a small fraction of the antibodies that exist in a natural immune repertoire and have limited […]
GigaGen Announces Appointment of Sheila M. Keating, Ph.D., as Director, Immunology
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Sheila M. Keating, Ph.D., has joined the company as Director, Immunology. Dr. Keating will lead clinical development of GigaGen’s recombinant hyperimmune gammaglobulin product in collaboration with pharmaceutical partner Grifols. Read the full press release.
GigaGen CEO David Johnson to Present on the Power of Surge Technology to Discover Unique Immuno-oncology Antibodies at 14th Annual PEGS Summit
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the discovery of unique and functional antibodies utilizing Surge technology at the 14th Annual PEGS Summit. Dr. Johnson’s invited podium presentation is titled “Discovery of High-Affinity Human PD-1 and LAG-3 Antibodies Using […]
GigaGen CEO David Johnson to Present Data from Surge Platform at American Association for Cancer Research Annual Meeting 2018
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present data from the company’s proprietary Surge platform at the American Association for Cancer Research (AACR) Annual Meeting 2018. The conference will take place April 14-18, 2018, at the McCormick Place in Chicago. Read the full […]
Nature Biotechnology: GigaGen Recognized as One of the Top Biotech Startups Funded in 2017
News, UncategorizedOur annual survey highlights how immune-oncology and screens based on the application of cutting-edge omics technologies are providing a launchpad for a succession of startups interrogating biology across biomedicine. Read the full story.
GigaGen Presents Methods for Rapid Immuno-Oncology Antibody Discovery at 2018 Keystone Symposia on Antibodies as Drugs
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, presented preclinical research on its industry-leading Surge™ technology at the 2018 Keystone Symposia on Antibodies as Drugs: Translating Molecules into Treatments. In its research, GigaGen used Surge, a high-throughput single cell droplet microfluidic technology, to rapidly discover high-affinity, fully human antibody drug candidates against 17 immuno-oncology […]
GigaGen Announces Appointment of Jan Fredrik Simons, Ph.D., as Senior Director, Technology
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Jan Fredrik Simons, Ph.D., has joined the company as Senior Director, Technology. Read the full press release.
Biotech Showcase 2018
News, UncategorizedDavid S. Johnson, PhD, MBA, Chief Executive Officer and Co-Founder, GigaGen, speaks to SCRIP about the company’s pipeline and business strategy. Watch the video.
GigaGen to Present Novel Antibody Development and T Cell Discovery Methods at 2018 Keystone Symposia Conferences
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, will be presenting the findings of its research on novel approaches to antibody development and T cell discovery for diseases of immune dysregulation at two upcoming Keystone Symposia conferences. The first conference, “Emerging Cellular Therapies: T Cells and Beyond,” will take place Feb. 11-15 in Keystone, […]
Life Science Leader: GigaGen CEO Dave Johnson discusses what Drug Developers can learn from Silicon Valley
News, UncategorizedI think Silicon Valley’s most valuable asset is a ruthless focus on experimenting with product- market fit. Silicon Valley software companies have the mentality of pushing out products, getting market feedback, and then going back to the drawing board if the market responds poorly. Imperfect products are a learning experience — an experiment — rather […]
Natively Paired Antibodies Are Better: Study by GigaGen in Collaboration with Global Biopharmaceutical Company Describes Novel Approach to Identifying Antibodies with High Therapeutic Potential
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing a pipeline of novel antibody therapies, has published a study in collaboration with authors from a leading antibody drug developer that sheds new light on methods for increasing the success of antibody discovery in mice. The study, “A natively paired antibody library yields drug leads with higher sensitivity and […]
GigaGen Announces New Office Space in South San Francisco
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that in order to expand operations it has moved to larger office facilities located at One Tower Place, Suite 750, in South San Francisco, CA. GigaGen now occupies the 7th floor of the building, with the roughly 15,000 square foot area affording ample state-of-the-art […]
GigaGen Receives NIH Grant to Develop Production Technology for Recombinant Intravenous Immunoglobulin
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, has been awarded a $3 million grant from the National Institutes of Health (NIH) to advance its next-generation plasma therapy for patients with immune deficiencies. GigaGen will use the funds to develop a natural repertoire antibody protein expression system, laying the foundation for a recombinant immunoglobulin […]
GigaGen to Develop Human Antibodies Against 17 Immuno-oncology Targets
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the disclosure of 17 immuno-oncology targets the company is pursuing within their robust internal pipeline. GigaGen has completed a large discovery and development effort of fully human antibody drug candidates against the following cancer targets: PD-1, LAG-3, OX40, CSF1R, ICOS, VISTA, CD47, B7-H4, CD27, […]